Although conjugation with polyethylene glycol (PEGylation) improves the pharmacokinetics of therapeutic proteins, it drastically decreases their bioactivity. Site-specific PEGylation counters the reduction in bioactivity, but developing PEGylated proteins with equivalent bioactivity to that of their unmodified counterparts remains challenging. This study aimed to generate PEGylated proteins with equivalent bioactivity to that of unmodified counterparts. Using interferon (IFN) as a model protein, a highly bioactive Lys-deficient protein variant generated using our unique directed evolution methods enables the design of a site-specific di-PEGylated protein. Antiviral activity of our di-PEGylated IFN was similar to that of unmodified IFN-α2b. The di-PEGylated IFN exhibited 3.0-fold greater antiviral activity than that of a commercial PEGylated IFN. Moreover, our di-PEGylated IFN showed higher in vitro and in vivo stability than those of unmodified IFN-α2b. Hence, we propose that highly bioactive Lys-deficient proteins solve the limitation of conventional PEGylation with respect to the reduction in bioactivity of PEGylated proteins.
W hile the conjugation of polyethylene glycol (PEG) to Lys residues in therapeutic proteins enhances their pharmacokinetics, 1−3 the drastic reduction in bioactivity remains a drawback. 4 Native proteins such as interferon (IFN) 5 show poor pharmacokinetics because they are eliminated rapidly in urine and are digested easily by proteases in the bloodstream. To overcome their poor pharmacokinetics, PEGylation has been applied to many proteins. 6 PEGylation increases the effective molecular weight of proteins, thereby reducing their elimination from the kidneys during filtration. 7 Furthermore, a PEGylated protein is protected from digestion owing to steric hindrance between a PEG moiety and a protease. Consequently, the half-lives of PEGylated proteins are prolonged dramatically. Nevertheless, conventional PEGylation methods decrease the bioactivity of PEGylated proteins because PEGylation randomly occurs on Lys residues and inhibits not only interactions with proteases but also those with target receptors. For example, only ∼28% and ∼7% of the antiviral-specific activity relative to that of unmodified IFN-α2b was retained by a commercial PEGylated IFN-α2b randomly conjugated to a linear 12-kDa PEG (PEGINTRON) and to a branched 40-kDa PEG (Pegasys), respectively. 8, 9 The bioactivity of PEGylated proteins decreases with an increase in the molecular weight of conjugated PEG. 10 In addition, for commercial use, homogeneous site-specific PEGylation conjugates are preferable because of easier characterization and scale-up.
Although site-specific mono-PEGylation can improve the bioactivity of PEGylated proteins compared to random PEGylation, it still decreases their bioactivities. 9−12 Sitespecific mono-PEGylation is more favorable than random PEGylation because PEG does not affect receptor binding except when it is directed toward receptor-binding sites. Even site-specific PEGylation, however, does not always result in PEGylated proteins with equivalent bioactivity to that of their unmodified counterparts.
N-terminal PEGylation 13 and PEGylation using unnatural amino acids (UAAs) 14, 15 are two attractive site-specific PEGylation methods reported thus far, as well as site-selective PEGylation methods including GlycoPEGylation using sialyltransferases, 16, 17 transglutaminase-based methods, 18, 19 and disulfide bridging approaches. 20 To accomplish N-terminal PEGylation, Yamamoto et al. 13 have used a directed evolution method and obtained a Lys-deficient tumor necrosis factor α (TNFα). Conjugating PEG to the N-terminus of the Lysdeficient TNFα, they developed a site-specific mono-PEGylated TNFα with comparable bioactivity to that of the wild-type (WT). The conventional directed evolution, however, is time-consuming for generating Lys-deficient proteins because the screening process cannot exclude protein variants possessing Lys from a library. Indeed, 191 of 197 active TNFα variants resulted from directed evolution were not Lys-deficient proteins. Therefore, an efficient method to obtain Lys-deficient proteins is required. Furthermore, positions other than the N-terminus could be preferable for PEGylation to retain bioactivity because of proximity to receptor recognition sites of proteins such as IFN-α2b. 8 Thus, PEGylation methods that can conjugate PEG in a site-specific manner on arbitrary sites is also required. Although incorporating UAAs into a protein enables site-specific PEGylation on arbitrary sites, 14, 15 the incorporation accuracy is lower than that of natural amino acids. 21 In addition, the safety of UAAs for humans is unclear. 22−24 Thus, a site-specific PEGylation method using only natural amino acids is preferable for therapeutic proteins.
This study aimed to develop a widely applicable method to generate PEGylated proteins with equivalent bioactivity to that of their unmodified counterparts. In this study, we hypothesized the following two points. First, site-specific PEGylation without a reduction in bioactivity is difficult to accomplish because among small proteins including IFN, most amino acid residues exposed to the solvent interact with its receptor. Therefore, we aimed to obtain a highly bioactive protein variant before PEGylation, which would aid the development of a PEGylated protein with sufficient bioactivity. Second, multi-PEGylation leads to higher stability than mono-PEGylation for the same total PEG molecular weight. For instance, although the total molecular weight was the same, a di-PEGylated IFN conjugated with two 5-kDa PEGs displayed increased protease tolerance than that of a mono-PEGylated IFN conjugated with one 10-kDa PEG, while their bioactivities were comparable. 14 Thus, we aimed to generate a di-PEGylated protein. To construct protein libraries wherein all variants lack Lys, we used the directed evolution methods including our original family helix shuffling (FH shuffling) and random mutagenesis with our simplified genetic code. 25 
■ RESULTS AND DISCUSSION
The Lys (K)-free IFN developed using FH shuffling and random mutagenesis with our simplified genetic code shows higher antiviral activity.
To obtain a highly bioactive Lys-deficient IFN variant required for site-specific di-PEGylation, we used FH shuffling and random mutagenesis with our simplified genetic code. Lysdeficient proteins enable site-specific PEGylation at arbitrary sites via substitution of an amino acid residue with Lys. Furthermore, high bioactivity is important for increasing the probability of obtaining a di-PEGylated IFN with equivalent activity to that of unmodified IFN-α2b, notwithstanding the reduction in activity upon PEGylation.
Using five cycles of directed evolution (one round of FH shuffling and random mutagenesis with our simplified genetic code, respectively, and three rounds of DNA shuffling 26 ), we obtained a highly bioactive Lys-deficient IFN variant, which is thereafter referred to as K-free IFN: K-free IFN displays a unique sequence (Supporting Information, Table S1 ) and showed a 3.5-fold and 4.8-fold increase in antiviral activity compared to that of IFN-α2b and to that of commercial IFN-α2b, respectively (P < 0.01, IC 50 = 29.5 ± 9.6, 103.1 ± 13.8, and 140.3 ± 15.4 fM of K-free IFN, IFN-α2b, and the commercial IFN-α2b, respectively, Figure 1 ). Although we fused the 6xHis-tag to the C-terminus of IFNs for purification, no significant differences in antiviral activity were observed between our IFN-α2b and commercial IFN-α2b without the His-tag (P > 0.2). In K-free IFN, highly conserved Lys residues in the IFN-α family are replaced with K34A, K53A, K74E, K87A, K125A, K137R, K138A, K163E, and K168A. Owing to the addition of DNA fragments containing AAR (Lys) to CGN (Ala) substitutions in FH shuffling, the K-free IFN easily contains these Ala replacements which require at least two nucleotide substitutions.
Generally, high-quality libraries of well-folded proteins are required in directed evolution. 28 FH shuffling, our original recombination method, may potentially increase the probability of obtaining IFN variants with proper three-dimensional structures. Thus, it is likely to enrich bioactive variants in a 
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Research Article library, simultaneously increasing sequence diversity in a library with an efficiency similar to that of DNA shuffling. The unique advantage of FH shuffling involves the recombination among IFN-α genes, each of which is separated into DNA sequences on the basis of the secondary structure elements ( Figure 2 and Figure S2 ). Because all IFN-α's consist of five helices and have a conserved topology, modification of the conserved structure would decrease their bioactivity. Hence, by aligning all sequences, we separated each sequence into protein fragments corresponding to one secondary structure element such as an A helix and an AB loop, and its flanking sequence. These Lys-deficient protein fragments were converted into DNA fragments for FH shuffling. In addition to these WT DNA sequences, we used corresponding DNA fragments from an IFN-α2b mutant gene where all 10 Lys codons were substituted with CGN (Ala). At certain positions, Lys residues are conserved in all IFN-αs. In this case, the conserved Lys codons in a corresponding IFN-α2b fragment were substituted with AGR (Arg). We also used these Arg-or Ala-modified DNA fragments in FH shuffling. Lys-deficient IFN genes resulting from FH shuffling were screened using the GFP-folding reporter assay to select properly folded IFN variants. 29 Among residues in our K-free IFN, we found unique amino acids, each of which was not present at their corresponding positions in the IFN-α family. For example, K31 and K133 are indeed critical for the bioactivity of IFN, 30 however, these Lys residues are substituted with Ala in our K-free IFN. Hence, although Lys is usually substituted with Arg because of their similar physicochemical properties, an Ala substitution would also help generate a Lys-deficient library. The K-free IFN contains rare residues, each present in only one subtype in the IFN-α family, such as N5 in IFN-α14, and R137 in IFN-α10.
Gly substitution at Glu41 generated via random mutagenesis is unique because all IFN-αs possess E41.
Random mutagenesis with our simplified genetic code facilitates the development of Lys-deficient IFN variants. On the basis of the universal genetic code, random mutagenesis carries the risk of generating AAR codons assigned to Lys, which we intended to eliminate from the library. Indeed, in the case of TNFα, nearly all of the active variants harbored Lys. 13 Conversely, in our simplified genetic code, AAR codons are assigned to Ala instead of Lys. Thus, our simplified genetic code can generate a library consisting only of Lys-deficient proteins.
Rather than using UAAs for site-specific PEGylation, 14, 15 our method has the advantage of authentic protein production systems with high translation fidelity 21 used for Lys-deficient proteins. Genes encoding Lys-deficient proteins evolved with our simplified genetic code may harbor AAR codons, which are assigned to Lys in the universal genetic code. However, those AAR codons can be easily substituted with CGN codons (Ala) by gene synthesis. Therefore, Lys-deficient proteins can be produced in authentic mass production systems such as E. coli and mammalian cells using the universal code. On the contrary, UAAs are problematic owing to their low incorporation rates, although PEGylation at arbitrary sites is also possible with UAAs. Generally, to incorporate UAAs into proteins of interest in cells, amber suppression by the orthogonal tRNA/tRNA synthetase pair is harnessed. 31, 32 In this case, the incorporation rate is not 100%, and it depends on the sequence context flanking the UAA incorporation site. The present method solves the risk of low incorporation rates because only natural amino acids are used.
In addition to site-specific modification using UAAs, a Cysselective modification method gained increasing attention for protein modification. 33 The simplified genetic code herein can Figure 2 . Flowchart of FH shuffling. A schematic representation of FH shuffling performed herein is shown. By aligning all IFN-α sequences, we separated each sequence into protein fragments corresponding to secondary structure elements such as an A helix and an AB loop. Thereafter, we extracted Lys-deficient protein fragments or substituted Lys codons with CGN (Ala) or AGR (Arg) in the protein fragments. Finally, we reversetranslated the protein fragments into DNA fragments, each of which encodes one secondary structure element and its flanking residues (Table S2) . With these fragments, overlap extension PCR was performed to generate genes encoding Lys-deficient IFN variants.
Research Article also help generate a library in which all protein variants lack Cys. Thus, Cys-specific PEGylation as well as Lys-specific PEGylation demonstrated in this paper is also possible using our simplified genetic code.
Exploration of PEGylation Sites To Develop PEGylated IFNs with Equivalent Antiviral Activity to That of Unmodified IFN-α2b. For site-specific PEGylation of our K-free IFN, we aimed to identify PEGylation residues, each of which can be substituted with Lys without loss of bioactivity. Previous site-specific PEGylated IFNs indicated candidate residues. 8, 12, 34, 35 From these candidates, we selected five residues (Q5, A31, H34, M111, and A134) as our initial PEGylation sites ( Figure 3A ). Mono-K IFN variants, where one of the above-mentioned residues was substituted with Lys were modified with a branched 20-kDa PEG (20k mono-PEG IFNs). The antiviral activity assay revealed that some of our initial 20k mono-PEG IFN variants exhibited a reasonable activity ( Figure 3B ). For example, our 20k mono-PEG IFN H34K retained 45% of the antiviral-specific activity of unmodified IFN-α2b. Moreover, its specific activity was higher than that of an IFN-α2b variant site-specifically conjugated with one branched 20-kDa PEG at H34 using another method. 14 Nevertheless, the activity of our 20k mono-PEG IFN H34K is insufficient to achieve our study objective because we aimed to generate a di-PEGylated IFN with equivalent bioactivity to that of unmodified IFN-α2b. Thus, we reduced the size of the PEG conjugated to the K-free IFN and included new PEGylation site candidates.
To identify additional appropriate positions for di-PEGylation, we referred to the three-dimensional structure of the IFN/IFNAR1/2 ternary complex 36 and to the reported IFN hotspots for IFNAR1/2 binding. 37, 38 Finally, we selected a second set of five candidates including residues which have not been PEGylated so far (Q20, G37, N45, D71, and R104, Figure 3A ). When modified with a linear 5-kDa PEG (5k mono-PEG IFNs), 2 of the 10 mono-K IFN variants, H34K and D71K, exhibited similar antiviral activity to that of unmodified IFN-α2b ( Figure 3B ). The specific bioactivity of the 5k mono-PEG IFN H34K and the 5k mono-PEG IFN D71K were 81% and 82% of that of unmodified IFN-α2b, respectively. H34 has been reported as a promising site for PEGylation. 8, 14 The second site, D71, is located opposite H34 in the three-dimensional structure of IFN ( Figure 3C ). To our knowledge, D71, which is conserved in all IFN-αs, has not been PEGylated so far. The three-dimensional model of the K-free IFN generated by homology modeling using Robetta. 39 The model is colored in a gradient from the N-(blue) to the C-(red) terminus. The positions of PEGylated amino acid residues are shown in the CPK model. H34 and D71, promising PEGylation sites in the K-free IFN, are highlighted. (B) Antiviral activity of unmodified IFNs (blank) and mono-PEG IFNs (gray, 5k mono-PEG IFNs; and black, 20k mono-PEG IFNs) are shown. Mono-K IFNs are IFN variants developed by substituting 1 of the 10 amino acid residues (Q5, Q20, A31, H34, G37, N45, D71, R104, M111, and A134) with Lys in the K-free IFN. These 10 residues were selected based on other papers and the IFN/IFNAR1/2 complex structure. We developed a 5k or 20k mono-PEG IFN via the site-specific conjugation of a 5-or 20-kDa PEG to the Lys in a mono-K IFN, respectively. Each bar represents the mean and standard error (n = 4). N.D: no data. (C) Positions of H34 and D71 in IFN in the IFN/IFNAR1/2 ternary complex (PDB ID: 3SE3). H34 and D71 are located opposite each other.
Research Article Antiviral Activity, Physicochemical Properties, in Vitro Stability, and Pharmacokinetics of Our Site-Specific Di-PEGylated IFN with Two Linear 5-kDa PEGs. We next attempted to confirm whether our site-specific di-PEGylated IFN (5k di-PEG IFN) exhibited equivalent antiviral activity to that of unmodified IFN-α2b, while also displaying higher stability. In our 5k di-PEG IFN, two positions, H34K and D71K, each of which accepts a 5-kDa PEG in the K-free IFN, are conjugated with one 5-kDa PEG, respectively. The specific activity of 5k di-PEG IFN relative to that of unmodified IFN-α2b was equal, while that of PEGINTRON was 0.34-fold (Figure 4 , IC 50 = 119.4 ± 13.7, 33.4 ± 6.6, 118.0 ± 7.4, and 354.4 ± 30.3 fM of IFN-α2b, di-K IFN, 5k di-PEG IFN, and PEGINTRON, respectively). Thus, antiviral activity of our 5k-di PEG IFN is 3.0-fold greater than that of PEGINTRON (P < 0.001). This result indicates that our 5k di-PEG IFN may have similar therapeutic activity to that of PEGINTRON at doses 70% lower than those used currently.
To determine whether di-PEGylation alters the secondary and ternary structures of proteins, we performed circular dichroism (CD) analysis. Concurrent with previous reports, 8, 40 few differences in CD spectra between di-K IFN and 5k di-PEG IFN indicate that PEGylation does not influence the secondary or ternary structure of protein ( Figure S3 ). Thus, our 5k di-PEG IFN would retain the structures similar to that of the unmodified di-K IFN.
In addition to the confirmation of di-PEGylation of 5k di-PEG IFN by SDS-PAGE ( Figure S1 ), matrix-assisted laser desorption ionization (MALDI) mass spectrometry (MS) analyses of peptide(s) generated via tryptic digestion of IFNs were performed to evaluate site-specific PEGylation. An MS spectrum showed a broad peak corresponding to di-PEGylated IFN ( Figure S4A ). Additionally, another minor peak in the spectrum indicates that the 5k mono-PEG IFN byproduct was probably generated via desorption of a PEG moiety during ionization or tryptic digestion, 41 or contaminated due to insufficient protein purification. Furthermore, to confirm sitespecific PEGylation at K34 and K71, obliteration of m/z peaks of a fragment containing K31 or K71, which was observed for unmodified di-K IFN, provided evidence for PEGylation. 15, 42 MALDI-MS results for 5k di-PEG IFN revealed that K31 and K71 were PEGylated with over 90% and 95% efficiency, respectively ( Figure S4B−D) . Although an N-terminal amine and an amine of the Lys side chain constitute potential PEGylation sites, the intensity ratio of the m/z fragments corresponding to the N-terminal fragment between the di-K IFN and the 5k di-PEG IFN was similar to that of another reference fragment (3.3 vs 2.8, Figure S4E ,F). Therefore, this research accomplished PEGylation at specific Lys residues reintroduced to the winner of directed evolution with our simplified genetic code.
Our 5k di-PEG IFN exhibited greater thermal stability and protease tolerance than the unmodified di-K IFN. Following incubation at 85°C for 30 min, the residual ratios of the 5k di-PEG IFN and PEGINTRON were 64% and 76%, respectively, while those of IFN-α2b and di-K IFN were 3% and 1%, respectively (P < 0.001, Figure 5A ). The residual ratios of the 5k di-PEG IFN and PEGINTRON after incubation with trypsin for 1 h were 50% and 66%, respectively, while those of IFN-α2b and di-K IFN were 20% and 11%, respectively (P < 0.001, Figure 5B ). Of note, our di-K IFN showed poorer thermal stability and protease tolerance than IFN-α2b, probably because the IFN variants were selected exclusively on the basis of antiviral activity during directed evolution. In addition to the improved thermal stability and protease tolerance that can be achieved by other PEGylation methods, our method retains bioactivity even after PEGylation ( Figure  4 ). 
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As expected, antiviral activity of serum IFN, in other words in vivo stability, of our 5k di-PEG IFN was better than that of unmodified di-K IFN when tested in male mice. Four hours after injection, the antiviral activity of serum IFN in both the 5k di-PEG IFN and PEGINTRON groups were maintained and showed a 1000-fold increase owing to PEGylation ( Figure  6 , P < 0.05). Even 10 h after injection, serum IFN from mice injected with our 5k di-PEG IFN exhibited equivalent antiviral activity to those of PEGINTRON. The similarity in the in vivo stability between PEGINTRON and 5k di-PEG IFN is concurrent with the result reported previously wherein the in vivo stability between mono-PEG IFN conjugated with linear 10 kDa PEG and di-PEG IFN conjugated with two linear 5 kDa PEGs was similar. 14 This result demonstrates that our di-PEGylation method enhances the in vivo stability of our proteins of interest. Thus, even though the total PEG size in the 5k di-PEG IFN is 2 kDa smaller than that of PEGINTRON, our 5k di-PEG IFN showed comparable in vitro and in vivo stability to PEGINTRON.
Lys-deficiency of our active mutant allowed us to design a di-PEGylated IFN in which two selected residues are PEGylated. Our strategy, site-specific PEGylation via a Lysdeficient protein, has a high degree of freedom for designing modification sites, while other site-specific PEGylation methods 43 exhibit limitations when choosing PEGylation sites. We were actually able to attempt PEGylation not only on previously reported positions as promising sites but also on novel ones. For example, to our knowledge, this is the first report of a novel promising PEGylation site: D71. Furthermore, our method could be applied to any kind of therapeutic protein and is useful especially for proteins of which N-terminal PEGylation is not preferable.
The key for the successful generation of the di-PEGylated IFN with equivalent antiviral activity to that of WT IFN-α2b is the high antiviral activity of starting K-free IFN and di-K IFN. This is because our 5k di-PEG IFN retains 0.28-fold antiviral activity compared to di-K IFN, while PEGINTRON has 0.34fold antiviral activity compared to IFN-α2b ( Figure 4) . Thus, the high bioactivity of unmodified proteins developed by directed evolution is probably essential if polymer-conjugation inevitably decreases to some extent bioactivity (Figure 1 ). It is reasonable to generate a highly bioactive protein via directed evolution rather than to search a PEGylation position from a limited number of Lys residues of a WT protein for polymer conjugation without loss of bioactivity. Nonetheless, to minimize the reduction in the antiviral activity due to PEGylation, optimization of PEGylation sites is required even after directed evolution. Hence, Lys-deficiency enabling PEGylation on arbitrary sites also contributes to the generation of di-PEGylated IFN with similar bioactivity to that of WT IFN-α2b.
Our purification method and fusion of a 6xHis-tag to the Cterminus can produce IFN-α2b with similar antiviral activity to that of the purchased IFN-α2b without the His-tag (Figure 1) . The 6xHis-tag rarely affect structures of its fusion proteins because the tag is small. 44 Thus, fusion of the 6xHis-tag to the C-terminus of IFN-α2b and our IFN variants would probably not affect both antiviral activity and stability. However, decreased activity of proteins because of this fusion has been also reported. 45 Therefore, the effects of the presence of the His-tag on the C-terminus of IFN-αs calls for further investigation in future studies.
Neutralizing antidrug antibodies (ADAs) are often problematic with respect to the clinical application of protein drugs including IFNs because the effect of administered proteins are attenuated by ADAs and autoimmune response also occurs. 46, 47 Although our IFN variants developed by directed evolution might induce ADAs in human bodies more strongly than native IFN-α2b because of their unique sequence, PEGylation generally reduces the immunogenicity of conjugated proteins due to its steric shielding effect on epitopes. 3, 48, 49 Consequently, the present di-PEG IFN is not likely to cause issues related to the immune response or ADAs. Future studies are required to investigate the immunogenicity of our PEGylated IFNs in vivo.
In conclusion, using IFN as a model protein, we demonstrated that the present novel PEGylation strategy via a highly bioactive Lys-deficient protein can generate sitespecific di-PEGylated protein drugs with similar bioactivity and improved stability compared to unmodified WT proteins. To our knowledge, this is the first report describing a site-specific di-PEGylated IFN variant with equivalent bioactivity to that of unmodified IFN-α2b. Our site-specific di-PEGylated IFN conjugated with two linear 5-kDa PEGs on K34 and K71 displayed similar thermal stability, protease tolerance, and in vivo stability in mice to PEGINTRON, a clinical heterogeneous PEGylated IFN-α2b conjugated with a linear 12-kDa PEG. In addition, our 5k di-PEG IFN showed 3.0-fold greater antiviral activity than that of PEGINTRON. Expansion of the genetic code, or the use of UAAs would enable site-specific protein modification. However, the method is limited in terms of the incorporation rate of UAAs into a protein, high cost of UAAs, and safety for humans. In contrast, the present simplified genetic code has a potential to address these issues. Our simplified genetic code can thus be applied to generate other Lys-deficient proteins such as TNFα and erythropoietin, thereby permitting the optimization of PEGylation sites for numerous proteins. Currently, we are attempting to generate multi-PEGylated therapeutic proteins such as tri-PEGylated IFN. 
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Research Article ■ EXPERIMENTAL PROCEDURES Materials. PEGylation chemicals, SUNBRIGHT ME-050GS and GL2−400GS2, were purchased from Yuka Sangyo, Tokyo, Japan. PEGINTRON was purchased from MSD, Tokyo, Japan. Reaction groups of both of the chemicals are N-hydroxysuccinimide. Commercially available IFN-α2b without a His-tag was purchased from Miltenyi Biotech, Bergisch Gladbach, Germany.
Methods. Protein Expression, Purification, and PEGylation. E. coli BL21 (DE3) Rosetta2 was used for gene expression. A gene encoding each IFN was inserted into the pET26b expression vector. To purify IFNs, a 6xHis-tag was fused to the C-terminus of IFNs. Plasmid-containing E. coli were cultured in Luria−Bertani medium with appropriate antibiotics until an O.D. 590 of 0.3−0.4 followed by the addition of IPTG (final concentration 1 mM). After 5 h at 37°C, cells were harvested by centrifugation. To purify IFN expressed in inclusion bodies, cell pellets were sonicated in a sonication buffer (40 mM Tris-HCl pH 7.6, 300 mM NaCl, 0.05% Triton-X 100) and centrifuged (12000 rpm for 5 min at 4°C). Inclusion bodies were washed in a wash buffer (40 mM Tris-HCl pH 7.6, 300 mM NaCl) and denatured with a guanidine buffer (6 M guanidine, 20 mM sodium phosphate pH 7.8, 500 mM NaCl, 4 mM dithiothreitol). After centrifugation (12000 rpm for 10 min at 16°C), the supernatant of the denatured samples was filtered using MILLEX (pore size 0.45 μm, Merck Millipore, Burlington, MS) followed by purification using Ni beads (His60 Ni Superflow Resin, TAKARA BIO, Shiga, Japan) under denaturing conditions. Denatured IFNs were refolded by dilution in a 20-fold excess volume of 0.8 M Arg-HCl buffer (pH 9.3) at 4°C, 50 followed by concentration with anion-exchange chromatography (Q Sepharose Fast Flow, GE Healthcare, Hatfield, UK) in a stepwise manner using an equilibration buffer (50 mM Tris-HCl pH 8.4) and an elution buffer (300 or 500 mM NaCl for WT IFN-α2b or IFN variants, respectively). After concentration, the protein was purified via subsequent anion-exchange chromatography (Resource Q, GE Healthcare) and a gradient consisting of an equilibration buffer (50 mM Tris-HCl pH 8.4) and an elution buffer (0−50% linear gradient of 1 M NaCl/50 mM Tris-HCl pH 8.4). The concentration of purified IFNs was determined using the BCA assay (Pierce BCA Protein Assay Kit, Thermo Fisher Scientific, Waltham, MA). The purity of IFNs was evaluated by SDS-PAGE ( Figure S1 ).
IFNs in 50 mM sodium borate buffer pH 9.0 were reacted with a 10-fold molar excess of PEGylation chemicals. The mixture was rotated for 2 h at 4°C. These two steps were repeated twice more (three times in total). Through the addition of 1 M glycine in the borate buffer, the reaction was stopped due to a 50-fold molar excess of glycine relative to PEG. PEGylation was confirmed by SDS-PAGE and iodine staining. 51 Antiviral Assay with Replicon Cells. Replicon (R6-FLR-N) cells were maintained as previously described. 27 For the antiviral assay, 3000 cells in 100 μL of the medium were inoculated into each well of a 96-well plate and incubated for 24 h followed by the addition of a dilution series of IFNs. After a 72 h incubation from the addition of IFNs, a luciferase assay was performed using the Steady-Glo Luciferase Assay System (Promega, Madison, WI) in accordance with the manufacturer's instructions. The IC 50 value was calculated using the Rodbard equation in ImageJ (NIH).
Directed Evolution. To obtain active Lys-deficient IFN variants, we combined the following directed evolution methods: FH shuffling (first round), DNA shuffling (second, third, and fifth rounds), and random mutagenesis using our simplified genetic code (fourth round). FH shuffling, which is based on family shuffling, 52 was performed with DNA fragments lacking Lys codons ( Figure 2 ). The amino acid sequences of all human IFN-α subtypes were downloaded from UniProt 53 and aligned with the Clustal Omega software/server (Table S1 ). 54 To generate Lys-deficient IFN variants using FH shuffling, we designed three types of DNA fragments (see Results and Discussion section, Figure S2 , and Table S2 ). DNA shuffling and random mutagenesis with our simplified genetic code were performed in accordance with Stemmer's protocol 26 and our previous study, 25 respectively. The sequence of the tRNA variant used to incorporate Ala into AAR codons in this study and the confirmation of insertion of Ala to AAR codons by amino acid composition analysis are shown in our patent. 55 IFN libraries were screened using the GFP-folding assay 29 or the antiviral assay described above. For screening using the antiviral assay, IFN variants were synthesized in the cell-free translation system 25 followed by the addition of a serial dilution of the IFN variants to Replicon cells without purification.
Evaluation of in Vitro and in Vivo Stability. The thermal stability and protease tolerance assays were performed in accordance with Kim's 56 and Ramon's protocols, 51 respectively. Gel images were quantified with ImageJ.
Four-week old male Balb/c mice weighing 15−20 g were purchased from Sankyo Lab, Nagano, Japan. IFNs at a concentration of 2 × 10 8 U/kg of body weight were administered to the mice using a single subcutaneous injection. The injection volume was 300 μL at maximum, which is below one-fifth of total blood volume of mice (about 1.5 mL). PBS was administered as a blank control in every experiment. Herein, a unit (U) was defined as the IC 50 (fM) × 100 (μL). Blood samples of approximately 100 μL were collected from the orbital venous plexus of the mice under anesthesia with isoflurane and stored at 4°C overnight. For one mouse, only two blood samples were collected with an interval of more than 2 h. The total volume of blood withdrawn from one mouse was less than 200 μL. Sampling time points were 30, 90, 180, 240, 420, and 600 min after administration. The mice were divided into three groups, depending on the sampling time points. For the first group, sampling time points for a mouse were 30 and 180 min after administration. For the second group, sampling time points were 90 and 240 min after administration. For the last group, sampling time points were 420 and 600 min after administration. Blood sampling from PBS-injected mice was performed in the same manner as that using IFN-injected mice. Thereafter, the samples were centrifuged (1200g for 30 min at 4°C) to separate serum from whole blood. The serum samples were sterilized via filtration using Ultrafree-MC (Merck Millipore). Residual IFN activity in the serum was evaluated using an antiviral assay. All animal experiments were conducted under the approval of the animal ethical committees of the Tokyo Institute of Technology. We also observed the ARRIVE guidelines (https://www.nc3rs.org.uk/arriveguidelines) and the guide for the care and use of laboratory animals, 8th edition (NIH).
MALDI-MS Analysis. After tryptic digestion of purified WT IFN-α2b (control), di-K IFN, and 5k di-PEG IFN overnight at 37°C, the reaction was quenched by the addition of
Research Article trifluoroacetic acid. Tryptic peptides, as well as full-length proteins before the digestion reaction, were desalted with a ZipTip μC 18 and applied to a MALDI mass spectrometer (rapifleX MALDI Tissuetyper, Bruker Daltonik GmbH, Bremen, Germany) using α-cyano-4-hydroxycinnamic acid as the matrix.
CD Measurement. CD of IFNs were measured using JASCO J-1100 CD spectrometer (JASCO, Tokyo, Japan) and a quartz-cuvette with a 0.1 cm optical path length (GL Sciences, Tokyo, Japan). Scanning speed was 500 nm/min. The number of accumulations was 16. The concentration of all measured IFNs were adjusted to 2 μM with PBS. Baseline levels were measured using PBS and subtracted from the IFN spectra.
Statistical Methods. P-values were calculated using the Tukey or Tukey−Kramer test. All quantitative experiments were performed at least in technical triplicates (n ≥ 3). Pvalues less than 0.05 were considered statistically significant. 
